Loading…
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $24M | $-450M | $-243M | $-370M | -80.8% | - | - |
| 2024 | $0M | $-298M | $-294M | $-257M | -113.1% | - | - |
| 2023 | $0M | $-157M | $-155M | $-134M | 45.7% | - | - |
| 2022 | $0M | $-114M | $-112M | $-110M | 57.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 24.05 |
| Operating Expense | 113.85 | 158.17 | 300.75 | 477.85 |
| Operating Income | -113.85 | -158.17 | -300.75 | -453.80 |
| EBITDA | -113.60 | -156.89 | -297.60 | -450.31 |
| EBIT | -113.85 | -158.17 | -300.75 | -453.80 |
| Pretax Income | -111.93 | -154.99 | -294.23 | -251.89 |
| Tax Provision | 0 | 0 | 0 | -8.56 |
| Net Income | -111.93 | -154.99 | -294.23 | -243.32 |
| Net Income Common Stockholders | -111.93 | -154.99 | -294.23 | -243.32 |
| Total Expenses | 113.85 | 158.17 | 300.75 | 477.85 |
| Interest Income | 1.99 | 3.37 | 12.02 | 14.18 |
| Research And Development | 101.30 | 137.68 | 265.55 | 386 |
| Selling General And Administration | 12.55 | 20.50 | 35.20 | 91.86 |
| Normalized EBITDA | -113.60 | -156.77 | -292.20 | -638.22 |
| Normalized Income | -111.93 | -154.87 | -288.83 | -424.84 |
| Basic EPS | -2.91 | -2.99 | -10.38 | 0 |
| Diluted EPS | -2.91 | -2.99 | -10.38 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 6.39 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0.03 |
| Total Unusual Items | 0 | -0.12 | -5.41 | 187.91 |
| Total Unusual Items Excluding Goodwill | 0 | -0.12 | -5.41 | 187.91 |
| Net Income From Continuing Operation Net Minority Interest | -111.93 | -154.99 | -294.23 | -243.32 |
| Reconciled Depreciation | 0.25 | 1.28 | 3.15 | 3.50 |
| Net Interest Income | 1.99 | 3.37 | 12.02 | 14.18 |
| Net Income From Continuing And Discontinued Operation | -111.93 | -154.99 | -294.23 | -243.32 |
| Total Operating Income As Reported | -113.85 | -158.17 | -300.75 | -453.80 |
| Diluted Average Shares | 38.41 | 51.84 | 28.34 | 0 |
| Basic Average Shares | 38.41 | 51.84 | 28.34 | 0 |
| Diluted NI Availto Com Stockholders | -111.93 | -154.99 | -294.23 | -243.32 |
| Net Income Including Noncontrolling Interests | -111.93 | -154.99 | -294.23 | -243.32 |
| Net Income Continuous Operations | -111.93 | -154.99 | -294.23 | -243.32 |
| Other Income Expense | -0.07 | -0.19 | -5.50 | 187.74 |
| Other Non Operating Income Expenses | -0.07 | -0.07 | -0.09 | -0.17 |
| Special Income Charges | 0 | 0 | 0 | 187.91 |
| Restructuring And Mergern Acquisition | 0 | 0 | 0 | -187.91 |
| Gain On Sale Of Security | 0 | -0.12 | -5.41 | 0 |
| Net Non Operating Interest Income Expense | 1.99 | 3.37 | 12.02 | 14.18 |
| Interest Income Non Operating | 1.99 | 3.37 | 12.02 | 14.18 |
| General And Administrative Expense | 12.55 | 20.50 | 35.20 | 91.86 |
| Other Gand A | 12.55 | 20.50 | 35.20 | 91.86 |
| Operating Revenue | 0 | 0 | 0 | 24.05 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Alumis Inc.this co. | ALMS | $2.9B | - | 7.95 | -80.8% | -6.02 |
| Beam Therapeutics Inc. | BEAM | $3.0B | - | 2.35 | -6.5% | -5.05 |
| Denali Therapeutics Inc. | DNLI | $3.0B | - | 2.87 | -50.6% | -3.93 |
| LifeStance Health Group, Inc. | LFST | $2.9B | 371.50 | 1.90 | 0.6% | 39.06 |
| Dyne Therapeutics, Inc. | DYN | $2.9B | - | 2.95 |
| -45.9% |
| -4.14 |
| Erasca, Inc. | ERAS | $2.8B | - | 7.96 | -38.3% | -20.28 |
| Arcutis Biotherapeutics, Inc. | ARQT | $2.8B | - | 14.56 | -8.5% | -352.93 |
| Haemonetics Corporation | HAE | $2.7B | 16.26 | 3.03 | 20.4% | 9.88 |
| Soleno Therapeutics, Inc. | SLNO | $2.7B | 135.33 | 6.13 | 4.6% | 145.68 |
| Peer Median | - | 135.33 | 2.99 | -7.5% | -4.04 | |